Related references
Note: Only part of the references are listed.European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
Richard J. Sylvester et al.
EUROPEAN UROLOGY (2021)
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A. Boorjian et al.
LANCET ONCOLOGY (2021)
Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study
Bas W. G. van Rhijn et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
An inverse association between the Mediterranean diet and bladder cancer risk: a pooled analysis of 13 cohort studies
Willem J. A. Witlox et al.
EUROPEAN JOURNAL OF NUTRITION (2020)
The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial
Askin Eroglu et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?
Anouk E. Hentschel et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)
An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting
Jeremy Yuen-Chun Teoh et al.
EUROPEAN UROLOGY (2020)
Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial NIMBUS
Marc-Oliver Grimm et al.
EUROPEAN UROLOGY (2020)
Fruit consumption and the risk of bladder cancer: A pooled analysis by the Bladder Cancer Epidemiology and Nutritional Determinants Study
Sylvia H. J. Jochems et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes
Charlotte S. Voskuilen et al.
EUROPEAN UROLOGY FOCUS (2020)
A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens
Andrea Mari et al.
BJU INTERNATIONAL (2019)
Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour
Rodrigo Suarez-Ibarrola et al.
BJU INTERNATIONAL (2019)
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial
Wei Shen Tan et al.
EUROPEAN UROLOGY (2019)
Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer
Aaron Brant et al.
WORLD JOURNAL OF UROLOGY (2019)
Combination of Intravesical Bacille Calmette-Guerin and Chemotherapy vs. Bacille Calmette-Guerin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis
Di Huang et al.
FRONTIERS IN ONCOLOGY (2019)
The epidemiology of bacille Calmette-Guerin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study
Emilie S. Larsen et al.
BJU INTERNATIONAL (2019)
Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy
Badrinath Konety et al.
EUROPEAN UROLOGY (2019)
Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer
David D'Andrea et al.
BJU INTERNATIONAL (2019)
Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer
F. Johannes P. van Valenberg et al.
EUROPEAN UROLOGY (2019)
The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial
Amr A. Elsawy et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2019)
Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors
Zhongbao Zhou et al.
WORLD JOURNAL OF UROLOGY (2019)
Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use
Patrick C. Gordon et al.
EUROPEAN UROLOGY FOCUS (2019)
Grading of Urothelial Carcinoma and The New World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016
Eva M. Comperat et al.
EUROPEAN UROLOGY FOCUS (2019)
What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review
Erik Veskimae et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study
Christopher Martin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study
Christopher Martin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results
Tony W. Trinh et al.
ABDOMINAL RADIOLOGY (2018)
Safety and efficacy of various strains of bacille Calmette-Guerin in the treatment of bladder tumours in standard clinical practice
M. Unda-Urzai et al.
ACTAS UROLOGICAS ESPANOLAS (2018)
One year of experience using the Paris System for Reporting Urinary Cytology
Julie Meilleroux et al.
CANCER CYTOPATHOLOGY (2018)
Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients
Judith Bosschieter et al.
EUROPEAN UROLOGY (2018)
Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)
Valeria Panebianco et al.
EUROPEAN UROLOGY (2018)
Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review
Marcus G. K. Cumberbatch et al.
EUROPEAN UROLOGY (2018)
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence SWOG S0337 Randomized Clinical Trial
Edward M. Messing et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project
Rodolfo Hurle et al.
JOURNAL OF UROLOGY (2018)
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought
J. Palou et al.
WORLD JOURNAL OF UROLOGY (2018)
An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer
Francesco Soria et al.
WORLD JOURNAL OF UROLOGY (2018)
A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort
Nour-al-dain Marzouka et al.
SCIENTIFIC REPORTS (2018)
An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups
Judith Bosschieter et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk BCG failure non muscle invasive bladder cancer: 3years follow-up outcomes
Marco Racioppi et al.
BMC CANCER (2018)
Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment
Gun Danielsson et al.
SCANDINAVIAN JOURNAL OF UROLOGY (2018)
Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy
Seung Bin Kim et al.
INVESTIGATIVE AND CLINICAL UROLOGY (2018)
Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis
Angelo Naselli et al.
EUROPEAN UROLOGY FOCUS (2018)
Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer
Renzo Colombo et al.
EUROPEAN UROLOGY FOCUS (2018)
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review
Viktor Soukup et al.
EUROPEAN UROLOGY (2017)
Holmium YAG Photocoagulation: Safe and Economical Alternative to Transurethral Resection in Small Nonmuscle-Invasive Bladder Tumors
Jorge Planelles Gomez et al.
JOURNAL OF ENDOUROLOGY (2017)
Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study
Laimonis Kavalieris et al.
JOURNAL OF UROLOGY (2017)
Efficacy of bacillus Calmette-Guerin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis
Brock E. Boehm et al.
JOURNAL OF UROLOGY (2017)
Comparative Effectiveness of Fluorescent Versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis
Roger Chou et al.
JOURNAL OF UROLOGY (2017)
How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial
Wojciech Krajewski et al.
QUALITY OF LIFE RESEARCH (2017)
Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy
Marco Moschini et al.
BJU INTERNATIONAL (2016)
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin
Paolo Gontero et al.
BJU INTERNATIONAL (2016)
Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer
Daniel Ramirez et al.
BJU INTERNATIONAL (2016)
Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
Rianne J. M. Lammers et al.
WORLD JOURNAL OF UROLOGY (2016)
Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin: results from European Organisation
Jorg R. Oddens et al.
BJU INTERNATIONAL (2016)
The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results
Seiji Naito et al.
EUROPEAN UROLOGY (2016)
Intravesical Bacillus Calmette-Guerin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study
Timo Marttila et al.
EUROPEAN UROLOGY (2016)
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
Richard J. Sylvester et al.
EUROPEAN UROLOGY (2016)
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin
Samantha Cambier et al.
EUROPEAN UROLOGY (2016)
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer
Tom J. H. Arends et al.
EUROPEAN UROLOGY (2016)
Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies
Frits H. M. van Osch et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2016)
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group
Ashish M. Kamat et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pioglitazone use and risk of bladder cancer: population based cohort study
Marco Tuccori et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Pioglitazone use and risk of bladder cancer: population based cohort study
Marco Tuccori et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder
Eero Kaasinen et al.
SCANDINAVIAN JOURNAL OF UROLOGY (2016)
Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guerin
Sumer Baltaci et al.
BJU INTERNATIONAL (2015)
Long-term Outcome of Patients with Frequently Recurrent Non-muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Guerin (BCG) or Alternating BCG and Interferon-α2b Instillations: Prospective Randomised FinnBladder-4 Study
Riikka Jarvinen et al.
EUROPEAN UROLOGY (2015)
Maintenance Therapy with 3-monthly Bacillus Calmette-Guerin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013
Luis Martinez-Pineiro et al.
EUROPEAN UROLOGY (2015)
Sequential Combination of Mitomycin C Plus Bacillus Calmette-Guerin (BCG) Is More Effective but More Toxic Than BCG Alone in Patients with Non-Muscle-invasive Bladder Cancer in Intermediate-and High-risk Patients: Final Outcome of CUETO 93009, a Randomized Prospective Trial
Eduardo Solsona et al.
EUROPEAN UROLOGY (2015)
Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients
Paolo Gontero et al.
EUROPEAN UROLOGY (2015)
Efficacy and Safety of MCNA in Patients with Nonmuscle Invasive Bladder Cancer at High Risk for Recurrence and Progression after Failed Treatment with bacillus Calmette-Guerin
Alvaro Morales et al.
JOURNAL OF UROLOGY (2015)
Clinical Outcomes of cT1 Micropapillary Bladder Cancer
Daniel L. Willis et al.
JOURNAL OF UROLOGY (2015)
Comparison of outcomes between ultrasonography and cystoscopy in the surveillance of patients with initially diagnosed TaG1-2 bladder cancers: A matched-pair analysis
Naoya Niwa et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
BCG-refractory vs. BCG-relapsing non muscle-invasive bladder cancer: A prospective cohort outcomes study
Harry W. Herr et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer
Faysal A. Yafi et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old
Eva Comperat et al.
VIRCHOWS ARCHIV (2015)
The prognostic value of family history among patients with urinary bladder cancer
Lieke Egbers et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy
Thierry Roumeguere et al.
TRANSPLANT INTERNATIONAL (2015)
Increased Lung and Bladder Cancer Incidence in Adults after In Utero and Early-Life Arsenic Exposure
Craig Steinmaus et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer
Mohamed Bishr et al.
CUAJ-Canadian Urological Association Journal (2014)
Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection
Thomas Seisen et al.
CURRENT OPINION IN UROLOGY (2014)
International Variations in Bladder Cancer Incidence and Mortality
Saurabh Chavan et al.
EUROPEAN UROLOGY (2014)
Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature
Joseph J. Crivelli et al.
EUROPEAN UROLOGY (2014)
Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG
Maurizio Brausi et al.
EUROPEAN UROLOGY (2014)
Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines
Beate Pesch et al.
INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH (2014)
Combined Chemohyperthermia: 10-Year Single Center Experience in 160 Patients with Nonmuscle Invasive Bladder Cancer
Tom J. H. Arends et al.
JOURNAL OF UROLOGY (2014)
Reproducibility and Prognostic Value of WHO1973 and WHO2004 Grading Systems in TaT1 Urothelial Carcinoma of the Urinary Bladder
Ok Malfrid Mangrud et al.
PLOS ONE (2014)
Recent Advances in Imaging Cancer of the Kidney and Urinary Tract
Susan Hilton et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology
Yann Neuzillet et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Immediate Post-Transurethral Resection of Bladder Tumor Intravesical Chemotherapy Prevents Non-Muscle-invasive Bladder Cancer Recurrences: An Updated Meta-analysis on 2548 Patients and Quality-of-Evidence Review
Nathan Perlis et al.
EUROPEAN UROLOGY (2013)
Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance
Jorg Oddens et al.
EUROPEAN UROLOGY (2013)
Perioperative Intravesical Chemotherapy in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Michael R. Ahern et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria
Harry W. Herr
BJU INTERNATIONAL (2012)
The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer
Mario Richterstetter et al.
BJU INTERNATIONAL (2012)
Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome
Polat Turker et al.
BJU INTERNATIONAL (2012)
Smoking Reduces the Efficacy of Intravesical Bacillus Calmette-Guerin Immunotherapy in Non-muscle-invasive Bladder Cancer
Michael Rink et al.
EUROPEAN UROLOGY (2012)
Follow-up After Surgical Treatment of Bladder Cancer: A Critical Analysis of the Literature
Viktor Soukup et al.
EUROPEAN UROLOGY (2012)
A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage
Bas W. G. van Rhijn et al.
EUROPEAN UROLOGY (2012)
Should Follow-up Cystoscopy in Bacillus Calmette-Guerin-Treated Patients Continue After Five Tumour-Free Years?
Sten Holmang et al.
EUROPEAN UROLOGY (2012)
Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Guerin
Joan Palou et al.
EUROPEAN UROLOGY (2012)
Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis
Graham Mowatt et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2011)
Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guerin
Sultan S. Alkhateeb et al.
UROLOGY ANNALS (2011)
Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin
Eleanor R. Ray et al.
BJU INTERNATIONAL (2010)
Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort
Hans-Martin Fritsche et al.
EUROPEAN UROLOGY (2010)
Bacillus Calmette-Guerin Is Superior to a Combination of Epirubicin and Interferon-alpha 2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study
Milos Duchek et al.
EUROPEAN UROLOGY (2010)
Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder
Richard J. Sylvester et al.
EUROPEAN UROLOGY (2010)
Photodynamic Diagnosis (5-Aminolevulinic Acid) of Transitional Cell Carcinoma After Bacillus Calmette-Guerin Immunotherapy and Mitomycin C Intravesical Therapy
Ronald O. P. Draga et al.
EUROPEAN UROLOGY (2010)
Detrusor Muscle in the First, Apparently Complete Transurethral Resection of Bladder Tumour Specimen Is a Surrogate Marker of Resection Quality, Predicts Risk of Early Recurrence, and Is Dependent on Operator Experience
Paramananthan Mariappan et al.
EUROPEAN UROLOGY (2010)
Cystoscopy Revisited as the Gold Standard for Detecting Bladder Cancer Recurrence: Diagnostic Review Bias in the Randomized, Prospective CEFUB Trial
Madelon N. M. van der Aa et al.
JOURNAL OF UROLOGY (2010)
Long-term Efficacy of Maintenance Bacillus Calmette-Guerin versus Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT1 Tumours without Carcinoma In Situ: A Subgroup Analysis of the Prospective, Randomised FinnBladder I Study with a 20-Year Follow-up
Riikka Jarvinen et al.
EUROPEAN UROLOGY (2009)
An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer
Per-Uno Malmstrom et al.
EUROPEAN UROLOGY (2009)
Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
Jesus Fernandez-Gomez et al.
JOURNAL OF UROLOGY (2009)
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer
Seth P. Lerner et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)
Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors
Juan Palou et al.
UROLOGY (2009)
The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: A systematic review of the published results of randomized clinical trials
Richard J. Sylvester et al.
EUROPEAN UROLOGY (2008)
Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events
J. Alfred Witjes et al.
EUROPEAN UROLOGY SUPPLEMENTS (2008)
Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder
Atsushi Takenaka et al.
INTERNATIONAL JOURNAL OF UROLOGY (2008)
Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy
Brian L. Gallagher et al.
UROLOGY (2008)
GRADE:: going from evidence to recommendations
Gordon H. Guyatt et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer:: Low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C
Antonio Ojea et al.
EUROPEAN UROLOGY (2007)
Management of low grade papillary bladder tumors
Harry W. Herr et al.
JOURNAL OF UROLOGY (2007)
Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer
Ganesh V. Raj et al.
JOURNAL OF UROLOGY (2007)
Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials
Rui Fa Han et al.
UROLOGY (2006)
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
RJ Sylvester et al.
EUROPEAN UROLOGY (2006)
Watchful waiting policy in recurrent Ta G1 bladder tumors
ON Gofrit et al.
EUROPEAN UROLOGY (2006)
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial
SM Di Stasi et al.
LANCET ONCOLOGY (2006)
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder
RJ Sylvester et al.
UROLOGY (2005)
Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder
MU Mungan et al.
EUROPEAN UROLOGY (2005)
Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?: Results of a prospective randomized trial
JA Martínez-Piñeiro et al.
JOURNAL OF UROLOGY (2005)
Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer
CP Brocks et al.
JOURNAL OF UROLOGY (2005)
Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor
J Palou et al.
JOURNAL OF UROLOGY (2005)
Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2005)
A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database
P Mariappan et al.
JOURNAL OF UROLOGY (2005)
Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer - The 6th trial of the Japanese Urological Cancer Research Group (JUCRG): A randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml
M Kuroda et al.
EUROPEAN UROLOGY (2004)
Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer:: Formal meta-analysis of comparative studies on tumor progression
A Böhle et al.
UROLOGY (2004)
Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials
MD Shelley et al.
BJU INTERNATIONAL (2004)
A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2004)
Maintenance bacillus Calmette-Guerin for TaT1 bladder tumors is not associated with increased toxicity: Results from a European organisation for research and treatment of cancer genito-urinary group phase III trial
APM van der Meijden et al.
EUROPEAN UROLOGY (2003)
Defining bacillus Calmette-Guerin refractory superficial bladder tumors
HW Herr et al.
JOURNAL OF UROLOGY (2003)
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity
A Bohle et al.
JOURNAL OF UROLOGY (2003)
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2002)
Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance
TRL Griffiths et al.
JOURNAL OF UROLOGY (2002)
Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer
JA Martínez-Piñeiro et al.
BJU INTERNATIONAL (2002)
Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo
A Bohle et al.
JOURNAL OF UROLOGY (2002)
A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer
MD Shelley et al.
BJU INTERNATIONAL (2001)
Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial
JLS Au et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Upper urinary tract tumors after primary superficial bladder tumors:: Prognostic factors and risk groups
F Millán-Rodríguez et al.
JOURNAL OF UROLOGY (2000)
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study
DL Lamm et al.
JOURNAL OF UROLOGY (2000)
Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: Long-term results
A Losa et al.
JOURNAL OF UROLOGY (2000)
Share Paper
